These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 25360654)
1. [Effects of dipeptidyl peptidase-4 on the hematopoiesis and transplantation]. Li DG; Meng AM Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2014 Oct; 36(5):538-41. PubMed ID: 25360654 [TBL] [Abstract][Full Text] [Related]
2. The role of dipeptidyl peptidase 4 in hematopoiesis and transplantation. O'Leary H; Ou X; Broxmeyer HE Curr Opin Hematol; 2013 Jul; 20(4):314-9. PubMed ID: 23594692 [TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides. Mentlein R Regul Pept; 1999 Nov; 85(1):9-24. PubMed ID: 10588446 [TBL] [Abstract][Full Text] [Related]
4. Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types. Ou X; O'Leary HA; Broxmeyer HE Blood; 2013 Jul; 122(2):161-9. PubMed ID: 23637126 [TBL] [Abstract][Full Text] [Related]
5. CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. Jungraithmayr W; De Meester I; Matheeussen V; Baerts L; Arni S; Weder W Eur J Cardiothorac Surg; 2012 May; 41(5):1166-73. PubMed ID: 22219460 [TBL] [Abstract][Full Text] [Related]
6. Modulation of Hematopoietic Chemokine Effects In Vitro and In Vivo by DPP-4/CD26. Broxmeyer HE; Capitano M; Campbell TB; Hangoc G; Cooper S Stem Cells Dev; 2016 Apr; 25(8):575-85. PubMed ID: 26943017 [TBL] [Abstract][Full Text] [Related]
7. Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy. Fadini GP; Albiero M; Seeger F; Poncina N; Menegazzo L; Angelini A; Castellani C; Thiene G; Agostini C; Cappellari R; Boscaro E; Zeiher A; Dimmeler S; Avogaro A Basic Res Cardiol; 2013 Jan; 108(1):313. PubMed ID: 23184393 [TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase IV (CD26) activity in the hematopoietic system: differences between the membrane-anchored and the released enzyme activity. Pereira DA; Gomes L; El-Cheikh MC; Borojevic R Braz J Med Biol Res; 2003 May; 36(5):567-78. PubMed ID: 12715075 [TBL] [Abstract][Full Text] [Related]
9. Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies. Jones B; Adams S; Miller GT; Jesson MI; Watanabe T; Wallner BP Blood; 2003 Sep; 102(5):1641-8. PubMed ID: 12738665 [TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase IV: development, design, synthesis and biological evaluation of inhibitors. Borloo M; De Meester I Verh K Acad Geneeskd Belg; 1994; 56(1):57-88. PubMed ID: 7911611 [TBL] [Abstract][Full Text] [Related]
11. Susceptibility of milk protein-derived peptides to dipeptidyl peptidase IV (DPP-IV) hydrolysis. Nongonierma AB; FitzGerald RJ Food Chem; 2014 Feb; 145():845-52. PubMed ID: 24128555 [TBL] [Abstract][Full Text] [Related]
12. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. Thomas L; Eckhardt M; Langkopf E; Tadayyon M; Himmelsbach F; Mark M J Pharmacol Exp Ther; 2008 Apr; 325(1):175-82. PubMed ID: 18223196 [TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine. Ludwig A; Schiemann F; Mentlein R; Lindner B; Brandt E J Leukoc Biol; 2002 Jul; 72(1):183-91. PubMed ID: 12101279 [TBL] [Abstract][Full Text] [Related]
14. Is CD26/dipeptidyl peptidase IV a really important molecule in T cell activation of a certain rat strain? Iwaki-Egawa S; Watanabe Y; Fujimoto Y Immunobiology; 1995 Nov; 194(4-5):429-42. PubMed ID: 8749235 [TBL] [Abstract][Full Text] [Related]
15. Counteracting the enzymatic activity of dipeptidylpeptidase 4 for potential therapeutic advantage, with an emphasis on cord blood transplantation. Broxmeyer HE Korean J Intern Med; 2013 Nov; 28(6):639-45. PubMed ID: 24307836 [TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Yazbeck R; Howarth GS; Abbott CA Trends Pharmacol Sci; 2009 Nov; 30(11):600-7. PubMed ID: 19837468 [TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase IV activity in commercial solutions of human serum albumin. Bar-Or D; Slone DS; Mains CW; Rael LT Anal Biochem; 2013 Oct; 441(1):13-7. PubMed ID: 23770236 [TBL] [Abstract][Full Text] [Related]
18. Effects of progenitor cell dose and preleukapheresis use of human recombinant granulocyte colony-stimulating factor on the recovery of hematopoiesis after blood stem cell autografting in children. Kawano Y; Takaue Y; Watanabe T; Saito S; Abe T; Hirao A; Sato J; Ninomiya T; Suzue T; Koyama T Exp Hematol; 1993 Jan; 21(1):103-8. PubMed ID: 7678082 [TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase IV inhibitory peptides generated in Spanish dry-cured ham. Gallego M; Aristoy MC; Toldrá F Meat Sci; 2014 Feb; 96(2 Pt A):757-61. PubMed ID: 24200567 [TBL] [Abstract][Full Text] [Related]
20. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells . Haas R; Murea S Cytokines Mol Ther; 1995 Dec; 1(4):249-70. PubMed ID: 9384679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]